STAR
Strides Pharma Science Limited
HealthcarePharmaceuticalsSmall cap
The story
Priced low, and the quarter and outlook show why. Cheap is the only leg working.
Overall read
5.8/10
Cheap & weak
The three reads · this quarter
Priced low, and the quarter and outlook show why. Cheap is the only leg working.
Overall read
5.8/10
Cheap & weak
The three reads · this quarter
Priced low, and the quarter and outlook show why. Cheap is the only leg working.
Overall read
5.8/10
Cheap & weak
The three reads · this quarter
The standing reads · change less often
Moat
Slim edge
Narrow moat based on manufacturing complexity and regulatory barriers, but limited by modest ROCE and financial leverage.
Key variables
No key-variables snapshot yet.
Walk the talk
Not enough tracked guidance to grade yet.
Controlled substances quota approval in H1 FY27 expected to unlock revenue ramp from H2 FY27.
Latest · newest first
1w ago · Product & Approvals
USFDA issues EIR for Bengaluru facility, indicating successful inspection.
4w ago · Business Update
Q1FY27 revenue Rs 12,654m, up 13% YoY; ex-US markets grew 17%.
03 Jul 2026 · M&A / Investment
Completed transaction related to Pivot Path.
Where it sits